Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)


 0.4 (0.79%)

Market Cap$7,065,729,411

10/27/16  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics Reports Third Quarter 2016 Financial Results 10/27/16

Read more

Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ISHL 2016 10/20/16

Read more


3rd Quarter 2016 Financial Results 10/27/16 4:30 p.m. ETView eventMorgan Stanley Global Healthcare Conference09/13/16 9:10 a.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources